KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Non-Current Assets (2016 - 2025)

Teva Pharmaceutical Industries' Non-Current Assets history spans 17 years, with the latest figure at $26.8 billion for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Assets changed 0.1% year-over-year to $26.8 billion, compared with a TTM value of $108.3 billion through Dec 2025, down 6.94%, and an annual FY2025 reading of $26.8 billion, changed 0.1% over the prior year.
  • Non-Current Assets for Q4 2025 was $26.8 billion at Teva Pharmaceutical Industries, down from $27.1 billion in the prior quarter.
  • The five-year high for Non-Current Assets was $36.6 billion in Q1 2021, with the low at $26.8 billion in Q4 2024.
  • Average Non-Current Assets over 5 years is $31.3 billion, with a median of $31.0 billion recorded in 2023.
  • Year-over-year, Non-Current Assets fell 13.83% in 2021 and then grew 0.1% in 2025.
  • Tracing TEVA's Non-Current Assets over 5 years: stood at $35.1 billion in 2021, then dropped by 8.93% to $32.0 billion in 2022, then fell by 3.02% to $31.0 billion in 2023, then decreased by 13.62% to $26.8 billion in 2024, then grew by 0.1% to $26.8 billion in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Non-Current Assets are $26.8 billion (Q4 2025), $27.1 billion (Q3 2025), and $27.5 billion (Q2 2025).